Home / Market News / $NBIX
fiscal.ai Corporate Catalyst Impact 65/100 ● positive

Analyst Price Target for Neurocrine Biosciences Increased

Nov 4, 2026, 12:38 PM UTC · Primary ticker $NBIX

Neurocrine Biosciences received an updated 12-month price target from analysts, increasing it to $209.27. This adjustment suggests a significant 44% upside potential for the company's stock, indicating a positive outlook from the analyst community.

Neurocrine Biosciences (NBIX) has seen its 12-month analyst price target raised to $209.27, implying a substantial 44% upside potential. This positive revision reflects increased confidence from the analyst community in the company's future performance and valuation. For traders, this could signal short-term positive momentum and potentially attract new investors, while long-term investors might view it as validation of their holdings. The key opportunity lies in the potential for the stock to trend towards this new target, though it's important to remember that analyst targets are not guarantees and market conditions can always shift.

$NBIX positive Analyst price target increase
Source: fiscal.ai
Join the waitlist for full signal validation →

Not financial advice. AI-generated analysis for informational purposes only.